DxTerity Buys Cancer Dx Rights from SourceMDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing technology company DxTerity Diagnostics said today that it has acquired the intellectual property rights to several blood-based cancer diagnostic tests from SourceMDx.

The IP covers gene expression assays for early diagnosis of breast and lung cancer and a test for determining survival and response to therapy for melanoma patients. They are covered by a portfolio of more than 30 US and international patent filings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.